Last reviewed · How we verify
NCT06261528: NO-FATIGUE
Study of Circadian Focused Light Therapy in Progressive Multiple Sclerosis
Phase 1 trial testing Light therapy in Progressive Multiple Sclerosis in 20 participants. Enrolling by invitation.
1 July 2026
Quick facts
| Lead sponsor | University of Texas Southwestern Medical Center |
|---|---|
| Phase | Phase 1 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 18 April 2024 |
| Primary completion | 1 July 2026 |
| Estimated completion | 1 July 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Light therapy
Conditions studied
- Progressive Multiple Sclerosis — all drugs for Progressive Multiple Sclerosis →
Sponsor
University of Texas Southwestern Medical Center
Who can join
18 and older, any sex, with Progressive Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is being done to determine if treatment with a novel form of light therapy is tolerated in patients with progressive multiple sclerosis. The goal of this trial to establish the safety profile of this light therapy while generating data on its impact on fatigue, as well as its mechanism of action. Fatigue is often a complex symptom in multiple sclerosis, without any FDA-approved direct therapy. Fatigue is traditionally treated with symptom management through a multidisciplinary team.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06261528
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Light therapy
Trials testing the same drug.
- NCT06009289 — Light and Sleep Fragmentation · Phase 4 · not yet recruiting
- NCT07462637 — Signature Response to Light Therapy in Unipolar and Bipolar Major Depressive Episode (MDE) · NA · not yet recruiting
- NCT06781593 — Combining Light Therapy and CPAP in Depression · NA · recruiting
- NCT06165549 — Light Therapy for Internet Gaming Disorder · NA · completed
- NCT05391503 — Light Therapy for Obsessive-compulsive Disorder (OCD) · NA · completed
Other recruiting trials for Progressive Multiple Sclerosis
Currently open trials in the same condition.
- NCT07282574 — A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrel · Phase 2 · recruiting
- NCT07139743 — Obe-cel in Refractory Progressive Forms of Multiple Sclerosis · Phase 1 · recruiting
- NCT06675864 — Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 · Phase 1, PHASE2 · recruiting
- NCT05811013 — Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis · NA · recruiting
- NCT05740722 — Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis · Phase 2 · recruiting
Other University of Texas Southwestern Medical Center trials
Trials by the same sponsor.
- NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain · recruiting
- NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB) · NA · not yet recruiting
- NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · not yet recruiting
- NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer · NA · not yet recruiting
- NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06261528 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
- Last refreshed: 31 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06261528.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing